Concepts (182)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Blood Pressure | 7 | 2020 | 2198 | 1.44 | Why? |
| Anticholesteremic Agents | 3 | 2019 | 186 | 1.40 | Why? |
| Hypertension | 15 | 2021 | 8895 | 1.14 | Why? |
| Cholesterol, LDL | 2 | 2019 | 499 | 1.11 | Why? |
| Antihypertensive Agents | 8 | 2021 | 1962 | 0.95 | Why? |
| Dyslipidemias | 2 | 2019 | 791 | 0.91 | Why? |
| Prehypertension | 1 | 2019 | 14 | 0.78 | Why? |
| Essential Hypertension | 1 | 2019 | 48 | 0.74 | Why? |
| Cardiovascular Diseases | 12 | 2020 | 11497 | 0.70 | Why? |
| Hyperaldosteronism | 2 | 2018 | 17 | 0.67 | Why? |
| Hyperuricemia | 1 | 2017 | 160 | 0.64 | Why? |
| Renin-Angiotensin System | 7 | 2021 | 3661 | 0.60 | Why? |
| Serine Proteinase Inhibitors | 1 | 2019 | 341 | 0.58 | Why? |
| Risk Reduction Behavior | 2 | 2020 | 946 | 0.57 | Why? |
| Uric Acid | 1 | 2017 | 285 | 0.55 | Why? |
| Chemokines | 1 | 2020 | 1095 | 0.54 | Why? |
| Myocardial Ischemia | 1 | 2019 | 781 | 0.47 | Why? |
| Atherosclerosis | 1 | 2019 | 768 | 0.44 | Why? |
| Aspirin | 1 | 2019 | 1043 | 0.43 | Why? |
| Frail Elderly | 2 | 2018 | 1427 | 0.42 | Why? |
| Antibodies, Monoclonal | 2 | 2019 | 8041 | 0.38 | Why? |
| Evidence-Based Medicine | 2 | 2019 | 3228 | 0.37 | Why? |
| Climate Change | 1 | 2017 | 901 | 0.36 | Why? |
| Proprotein Convertase 9 | 2 | 2019 | 141 | 0.34 | Why? |
| Cardiology | 2 | 2020 | 2873 | 0.33 | Why? |
| Vitamin D | 2 | 2020 | 2904 | 0.33 | Why? |
| Atrial Fibrillation | 2 | 2018 | 2320 | 0.32 | Why? |
| Dietary Supplements | 1 | 2019 | 2251 | 0.31 | Why? |
| Vitamin D Deficiency | 1 | 2020 | 1782 | 0.31 | Why? |
| Environmental Exposure | 1 | 2017 | 1558 | 0.30 | Why? |
| Angiotensin-Converting Enzyme Inhibitors | 4 | 2021 | 5277 | 0.24 | Why? |
| Aging | 1 | 2018 | 3581 | 0.23 | Why? |
| Nutrition Surveys | 2 | 2020 | 287 | 0.22 | Why? |
| Ezetimibe | 2 | 2018 | 50 | 0.22 | Why? |
| Hydrocortisone | 1 | 2012 | 1790 | 0.22 | Why? |
| Anticoagulants | 2 | 2020 | 9563 | 0.20 | Why? |
| Endothelins | 1 | 2019 | 21 | 0.20 | Why? |
| Risk Factors | 14 | 2021 | 71621 | 0.20 | Why? |
| Angiotensin Receptor Antagonists | 3 | 2021 | 3892 | 0.20 | Why? |
| Endothelin-1 | 1 | 2019 | 69 | 0.19 | Why? |
| Angiotensins | 1 | 2021 | 259 | 0.19 | Why? |
| Recommended Dietary Allowances | 1 | 2019 | 43 | 0.19 | Why? |
| Glycolipids | 1 | 2018 | 19 | 0.19 | Why? |
| alpha-Galactosidase | 1 | 2018 | 32 | 0.19 | Why? |
| Arterial Pressure | 1 | 2021 | 208 | 0.19 | Why? |
| Geriatric Assessment | 2 | 2018 | 1372 | 0.19 | Why? |
| Nutritive Value | 1 | 2019 | 100 | 0.18 | Why? |
| Adrenalectomy | 1 | 2018 | 32 | 0.18 | Why? |
| Sphingolipids | 1 | 2018 | 59 | 0.18 | Why? |
| Blood Pressure Determination | 2 | 2019 | 450 | 0.18 | Why? |
| Air Pollution | 1 | 2017 | 3504 | 0.18 | Why? |
| Breast Neoplasms | 1 | 2016 | 3633 | 0.17 | Why? |
| Stroke | 2 | 2018 | 8839 | 0.17 | Why? |
| Fabry Disease | 1 | 2018 | 106 | 0.17 | Why? |
| Greenhouse Gases | 1 | 2017 | 59 | 0.17 | Why? |
| Receptors, Calcitriol | 1 | 2017 | 102 | 0.17 | Why? |
| Cardiovascular Surgical Procedures | 1 | 2020 | 281 | 0.16 | Why? |
| Periodontitis | 1 | 2019 | 171 | 0.16 | Why? |
| Renal Insufficiency, Chronic | 3 | 2021 | 2654 | 0.16 | Why? |
| Gout | 1 | 2017 | 85 | 0.16 | Why? |
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 2 | 2018 | 1510 | 0.15 | Why? |
| Treatment Outcome | 7 | 2021 | 51732 | 0.15 | Why? |
| Systole | 1 | 2017 | 252 | 0.15 | Why? |
| Blood Vessels | 1 | 2018 | 228 | 0.15 | Why? |
| Exercise | 1 | 2016 | 6771 | 0.15 | Why? |
| Consensus | 3 | 2020 | 6345 | 0.14 | Why? |
| Conservative Treatment | 1 | 2018 | 349 | 0.14 | Why? |
| Preventive Health Services | 1 | 2020 | 501 | 0.14 | Why? |
| Pharmacies | 1 | 2019 | 356 | 0.14 | Why? |
| Polyphenols | 1 | 2018 | 283 | 0.13 | Why? |
| Humans | 38 | 2021 | 930598 | 0.13 | Why? |
| Cardiovascular Agents | 1 | 2020 | 663 | 0.13 | Why? |
| Physical Fitness | 1 | 2017 | 334 | 0.13 | Why? |
| Antibodies, Monoclonal, Humanized | 3 | 2020 | 9335 | 0.13 | Why? |
| Protective Factors | 1 | 2019 | 1720 | 0.12 | Why? |
| Receptors, Interleukin-6 | 1 | 2020 | 1383 | 0.12 | Why? |
| Primary Prevention | 1 | 2019 | 778 | 0.12 | Why? |
| Ferritins | 1 | 2021 | 2055 | 0.12 | Why? |
| Interleukin 1 Receptor Antagonist Protein | 1 | 2020 | 1165 | 0.12 | Why? |
| Impotence, Vasculogenic | 1 | 2010 | 3 | 0.11 | Why? |
| Treatment Failure | 1 | 2018 | 2106 | 0.11 | Why? |
| Age Factors | 5 | 2021 | 21039 | 0.11 | Why? |
| Betacoronavirus | 6 | 2020 | 204454 | 0.11 | Why? |
| Italy | 12 | 2021 | 38444 | 0.11 | Why? |
| Frailty | 2 | 2021 | 1432 | 0.10 | Why? |
| Practice Guidelines as Topic | 3 | 2019 | 15421 | 0.10 | Why? |
| Hot Temperature | 1 | 2017 | 1299 | 0.09 | Why? |
| Multiple Myeloma | 1 | 2018 | 1064 | 0.09 | Why? |
| Carbolines | 1 | 2006 | 7 | 0.09 | Why? |
| Pneumonia, Viral | 6 | 2020 | 243684 | 0.09 | Why? |
| Cyclic Nucleotide Phosphodiesterases, Type 5 | 1 | 2006 | 24 | 0.08 | Why? |
| Aged, 80 and over | 9 | 2021 | 88759 | 0.08 | Why? |
| Coronavirus Infections | 6 | 2020 | 253789 | 0.08 | Why? |
| Ultrasonography, Doppler | 1 | 2010 | 406 | 0.08 | Why? |
| Exercise Therapy | 1 | 2016 | 976 | 0.08 | Why? |
| Biomarkers | 3 | 2019 | 23361 | 0.08 | Why? |
| Phosphodiesterase Inhibitors | 1 | 2006 | 61 | 0.08 | Why? |
| Societies, Medical | 2 | 2020 | 6907 | 0.08 | Why? |
| Aged | 13 | 2021 | 215776 | 0.08 | Why? |
| Neovascularization, Physiologic | 1 | 2006 | 160 | 0.08 | Why? |
| Hemorrhage | 1 | 2018 | 3013 | 0.07 | Why? |
| Diet | 1 | 2018 | 2052 | 0.07 | Why? |
| Erectile Dysfunction | 1 | 2006 | 141 | 0.07 | Why? |
| Life Style | 1 | 2018 | 2708 | 0.07 | Why? |
| Glucocorticoids | 1 | 2020 | 4431 | 0.07 | Why? |
| Acute Coronary Syndrome | 1 | 2018 | 2107 | 0.07 | Why? |
| Severity of Illness Index | 3 | 2021 | 48226 | 0.07 | Why? |
| Drug Therapy, Combination | 1 | 2018 | 7268 | 0.07 | Why? |
| Patient Admission | 1 | 2020 | 5250 | 0.06 | Why? |
| Animals | 4 | 2020 | 78931 | 0.06 | Why? |
| Female | 13 | 2021 | 380317 | 0.06 | Why? |
| Heart Failure | 2 | 2021 | 6638 | 0.06 | Why? |
| Patient Selection | 1 | 2017 | 4560 | 0.06 | Why? |
| Male | 14 | 2021 | 367725 | 0.06 | Why? |
| Adolescent | 6 | 2021 | 86841 | 0.05 | Why? |
| Comorbidity | 3 | 2021 | 34796 | 0.05 | Why? |
| Risk Assessment | 3 | 2021 | 25439 | 0.05 | Why? |
| Brain | 1 | 2018 | 5133 | 0.05 | Why? |
| Young Adult | 6 | 2021 | 93724 | 0.05 | Why? |
| Inflammatory Bowel Diseases | 1 | 2017 | 3209 | 0.05 | Why? |
| Disease Progression | 1 | 2019 | 13580 | 0.05 | Why? |
| Ezetimibe, Simvastatin Drug Combination | 1 | 2018 | 6 | 0.05 | Why? |
| Adult | 11 | 2021 | 244371 | 0.05 | Why? |
| Middle Aged | 12 | 2021 | 270681 | 0.05 | Why? |
| Sex Factors | 3 | 2021 | 11014 | 0.04 | Why? |
| Clinical Trials as Topic | 1 | 2018 | 7330 | 0.04 | Why? |
| Mutation | 1 | 2018 | 12376 | 0.04 | Why? |
| Thrombosis | 1 | 2020 | 7504 | 0.04 | Why? |
| Analysis of Variance | 1 | 2021 | 950 | 0.04 | Why? |
| Death | 1 | 2020 | 334 | 0.04 | Why? |
| Hydroxychloroquine | 1 | 2020 | 12447 | 0.04 | Why? |
| Hospital Mortality | 1 | 2020 | 22087 | 0.04 | Why? |
| Endothelial Cells | 1 | 2006 | 2048 | 0.04 | Why? |
| Cross-Sectional Studies | 5 | 2021 | 53120 | 0.04 | Why? |
| Hypolipidemic Agents | 1 | 2018 | 208 | 0.04 | Why? |
| Time | 1 | 2018 | 631 | 0.04 | Why? |
| Pandemics | 7 | 2021 | 389249 | 0.04 | Why? |
| Cardiotoxicity | 1 | 2018 | 365 | 0.04 | Why? |
| Multimorbidity | 1 | 2020 | 703 | 0.04 | Why? |
| Tomography, X-Ray Computed | 1 | 2021 | 25144 | 0.03 | Why? |
| Intensive Care Units | 1 | 2020 | 29594 | 0.03 | Why? |
| Global Health | 1 | 2017 | 13911 | 0.03 | Why? |
| Prevalence | 3 | 2020 | 25773 | 0.03 | Why? |
| Alleles | 1 | 2018 | 1557 | 0.03 | Why? |
| Hospitalization | 2 | 2021 | 54280 | 0.03 | Why? |
| Lung | 1 | 2021 | 31049 | 0.03 | Why? |
| Amino Acid Substitution | 1 | 2018 | 1706 | 0.03 | Why? |
| Retrospective Studies | 2 | 2020 | 105322 | 0.03 | Why? |
| Public Health | 1 | 2017 | 16359 | 0.03 | Why? |
| Age Distribution | 1 | 2020 | 3567 | 0.03 | Why? |
| Cost of Illness | 1 | 2020 | 1903 | 0.02 | Why? |
| Molecular Targeted Therapy | 1 | 2018 | 1579 | 0.02 | Why? |
| Aftercare | 1 | 2018 | 1637 | 0.02 | Why? |
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2018 | 1573 | 0.02 | Why? |
| Tadalafil | 1 | 2006 | 18 | 0.02 | Why? |
| Phenotype | 1 | 2018 | 4037 | 0.02 | Why? |
| Platelet Aggregation Inhibitors | 1 | 2018 | 1671 | 0.02 | Why? |
| Antiviral Agents | 1 | 2020 | 41703 | 0.02 | Why? |
| Genotype | 1 | 2018 | 4697 | 0.02 | Why? |
| Brachial Artery | 1 | 2006 | 107 | 0.02 | Why? |
| Chronic Disease | 1 | 2021 | 5139 | 0.02 | Why? |
| Phosphodiesterase 5 Inhibitors | 1 | 2006 | 104 | 0.02 | Why? |
| Risk | 1 | 2018 | 5288 | 0.02 | Why? |
| Survival Rate | 1 | 2020 | 9206 | 0.02 | Why? |
| Prognosis | 2 | 2020 | 32490 | 0.02 | Why? |
| Hypoglycemic Agents | 1 | 2018 | 2165 | 0.02 | Why? |
| Public Health Surveillance | 1 | 2018 | 3129 | 0.02 | Why? |
| Vasodilation | 1 | 2006 | 258 | 0.02 | Why? |
| Surveys and Questionnaires | 2 | 2021 | 43792 | 0.01 | Why? |
| Longitudinal Studies | 1 | 2018 | 9893 | 0.01 | Why? |
| Europe | 1 | 2018 | 12702 | 0.01 | Why? |
| Signal Transduction | 1 | 2017 | 7207 | 0.01 | Why? |
| Socioeconomic Factors | 1 | 2018 | 8495 | 0.01 | Why? |
| Host-Pathogen Interactions | 1 | 2020 | 11041 | 0.01 | Why? |
| Obesity | 1 | 2020 | 7388 | 0.01 | Why? |
| Prospective Studies | 2 | 2018 | 43301 | 0.01 | Why? |
| Infant, Newborn | 1 | 2018 | 23105 | 0.01 | Why? |
| Incidence | 1 | 2018 | 25622 | 0.01 | Why? |
| Infant | 1 | 2018 | 30274 | 0.01 | Why? |
| Child, Preschool | 1 | 2018 | 36283 | 0.01 | Why? |
| Ultrasonography | 1 | 2006 | 4409 | 0.01 | Why? |
| Child | 1 | 2018 | 70012 | 0.01 | Why? |
Ferri's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts
(182)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(74)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_